Principal Scientist Genentech, Inc. South San Francisco, California
The field of Immuno-oncology is in its relative infancy, but has already made a huge impact for patients. The initial wave of therapeutics is driven principally by biologics. Subsequent waves of improvements will be realized through combinations. This lecture will explore the role of Small Molecules to further drive scientific advances that can bring even more benefit for patients.
Upon completion, participants will be able to understand the impact of immuno-oncology treatments for patients and why additional advances are needed.
Upon completion, participants will be able to appreciate that small-molecules can play a big role in the identification of improved therapies that can provide more durable treatments for a greater number of patients.
Upon completion, participants will be able to understand that the identification of drugs for novel immuno-oncology targets will radically advance this promising field